Use of total lymphocyte count for monitoring response to antiretroviral therapy
- PMID: 14699459
- DOI: 10.1086/380792
Use of total lymphocyte count for monitoring response to antiretroviral therapy
Abstract
The CD4 cell count has become a key laboratory measurement in the management of human immunodeficiency virus (HIV) disease. In ideal situations, HIV-infected persons are followed up longitudinally with serial CD4 cell counts to determine disease progression, risk for opportunistic infection, and the need for prophylactic or therapeutic intervention. However, the use of the CD4 cell count in resource-limited settings is often not possible because of lack of availability and high cost. Thus, other laboratory markers have been proposed as substitutes for the CD4 cell count. The data regarding the clinical utility of the total lymphocyte count (TLC) as a potential surrogate marker of immune function in patients with HIV disease are examined. The role of the TLC in the initiation of antiretroviral therapy and opportunistic infection prophylaxis, as well as the role of the TLC in monitoring the response to antiretroviral therapy, are also addressed.
Similar articles
-
[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Enferm Infecc Microbiol Clin. 2009. PMID: 19246124 Spanish.
-
API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India.J Assoc Physicians India. 2006 Jan;54:57-74. J Assoc Physicians India. 2006. PMID: 16649742 Review.
-
Correlation of mucocutaneous manifestations of HIV/AIDS infection with CD4 counts and disease progression.Int J Dermatol. 2007 Oct;46 Suppl 2:14-8. doi: 10.1111/j.1365-4632.2007.03349.x. Int J Dermatol. 2007. PMID: 17958624
-
Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings?Clin Infect Dis. 2007 Jan 1;44(1):135-8. doi: 10.1086/510072. Epub 2006 Nov 28. Clin Infect Dis. 2007. PMID: 17143829
-
Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.Clin Infect Dis. 2005 Jun 15;40(12):e101-9. doi: 10.1086/430445. Epub 2005 May 5. Clin Infect Dis. 2005. PMID: 15909251
Cited by
-
Evaluating total lymphocyte count as a surrogate marker for CD4 cell count in the management of HIV-infected patients in resource-limited settings: a study from China.PLoS One. 2013 Jul 18;8(7):e69704. doi: 10.1371/journal.pone.0069704. Print 2013. PLoS One. 2013. PMID: 23874985 Free PMC article.
-
The effects of setarud on the immunological status of HIV-positive patients: Efficacy of a novel multi-herbal drug.Avicenna J Phytomed. 2017 May-Jun;7(3):232-241. Avicenna J Phytomed. 2017. PMID: 28748170 Free PMC article.
-
Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe.PLoS One. 2012;7(4):e33672. doi: 10.1371/journal.pone.0033672. Epub 2012 Apr 24. PLoS One. 2012. PMID: 22545079 Free PMC article. Clinical Trial.
-
Prevalence of anaemia and immunological markers among ghanaian HAART-naïve HIV-patients and those on HAART.Afr Health Sci. 2011 Mar;11(1):2-15. Afr Health Sci. 2011. PMID: 21572851 Free PMC article.
-
Clinical predictor score to identify patients at risk of poor viral load suppression at six months on antiretroviral therapy: results from a prospective cohort study in Johannesburg, South Africa.Clin Epidemiol. 2019 May 7;11:359-373. doi: 10.2147/CLEP.S197741. eCollection 2019. Clin Epidemiol. 2019. PMID: 31191029 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials